Immune Design Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3
Founded: Seattle WA United States (2008)
Status: Acquired by Merck (2019)

Organization Overview

First Clinical Trial
2008
NCT00111514
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

IDRI | IDRI Corporation | Immune Design